Corporate deck highlights IL-1β inhibitor strategy and trial results
Avalo outlined an IL-1β inhibitor strategy for immune-mediated inflammatory diseases, led by abdakibart in moderate-to-severe hidradenitis suppurativa.
Phase 2 LOTUS met its primary endpoint, with 42.5% HiSCR75 at week 16 versus 25.6% for placebo across dose arms.
HiSCR50 reached 61.7% across dose arms versus 40.7% for placebo; abdakibart was described as well tolerated with no neutropenia signal.
Phase 3 initiation targeted for 1H 2027; AVTX-010 expected to advance to IND in 1H 2027.
May 2026 financing totaled $431.3 million; cash runway expected to fund operations into 2029, including anticipated Phase 3 topline data.
AVTX•
